Acumen Pharmaceuticals : Corporate Presentation

Corporate Presentation

March 2023

1

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and

should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans,"

"potential," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business, Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the sufficiency of its cash resources, and the therapeutic potential of Acumen's product candidate, ACU193, including its potential for improved safety and efficacy as compared to other monoclonal antibodies in development, as well as the expectations concerning the INTERCEPT-AD trial and Acumen's planned Phase 2/3 clinical trial, including the expected timing of initiation, enrollment and reporting data, and risks and uncertainties relating to the progression and duration of the COVID-19 pandemic and responsive measures thereto and related effects on Acumen. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's most recent Annual Report Form 10-K and future filings and reports by Acumen. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward- looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward- looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. In this presentation, references to cash also include cash equivalents.

2

Advancing a Potential Best-/First-In-Class Antibody Product for

Early Alzheimer's disease (AD)

								$
•	Large market	•	Amyloid-beta	ACU193: First,	•	Experienced	•	Strong	•	Phase 1
•	High unmet		oligomers	clinical-stage		leadership		balance sheet:		clinical trial in
	(AβOs)	monoclonal		team		~$193M in		early AD
	need
		accepted as	antibody (mAb)	•	AD clinical,		cash at 31-		patients
•			most toxic	to selectively		Dec-22		ongoing
Recent			drug
	form of Aβ
	scientific &		target AβOs		development,	•	July 2021 IPO	•	Topline results
	•	Novel target
	regulatory			& regulatory		~$184M		expected Q3
	momentum		for effective			leaders from		gross		2023
			AD treatment			Eli Lilly & Co.

We believe that Acumen has the organizational expertise and fiscal resources to advance ACU193

through 2025.

3

Acumen Business Strategy: 2023 - 2025

• Rapidly advance ACU193 through clinical development in patients with early AD;
• Evaluate combination approaches to complement our core ACU193 monotherapy strategy;
• Expand our product portfolio by in-licensing and/or developing additional candidates and/or alternative formulations for, or derivatives of, ACU193; and
• Optimize value of ACU193 and future drug candidates in major markets.

4

INTERCEPT-AD Trial Update - February 2023

• INTERCEPT-AD:Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease (AD) (RCT)
• • Topline results, safety and clinical proof-of-mechanism following full database lock expected in Q3 2023
  • Enrollment completed in February 2023
  • Cohort 7 dose level amended to 25 mg/kg every two weeks (Q2W) from 60 mg/kg Q2W prior to start
  • • Preliminary, blinded plasma pharmacokinetic (PK) data demonstrated higher-than-expected ACU193 exposures at all dose levels
    • Preliminary Cohort 3 (SAD 25 mg/kg) dose results in Day 21 cerebrospinal fluid (CSF) ACU193 levels in excess of reported soluble amyloid beta oligomer (AβO) levels
    • Two blinded observations of asymptomatic ARIA-E factored into decision to amend Cohort 7 dose; one in Cohort 4 (after single 60 mg/kg dose) and one in Cohort 5 (after third 10 mg/kg dose)
    • Cohort 6 is fully enrolled with planned dose (60 mg/kg every four weeks (Q4W))

Safety profile to date remains supportive of targeting soluble amyloid beta oligomers and, combined with the

selectivity of ACU193, is expected to offer a favorable benefit-to-risk ratio for patients with early AD.

5